G Protein–Coupled Receptor Connectivity to NF-κB in Inflammation and Cancer

REFERENCES

• Hoffmann A., Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006; 210: 171–186
   PubMed Web of Science ®Google Scholar
• Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280–288
   PubMed Web of Science ®Google Scholar
• Hayden M. S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344–362
   PubMed Web of Science ®Google Scholar
• Perkins N. D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49–62
   PubMed Web of Science ®Google Scholar
• Hoffmann A., Natoli G., Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 2006; 25: 6706–6716
   PubMed Web of Science ®Google Scholar
• Ferrell J. E., Jr. Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends Biochem Sci 1996; 21: 460–466
   PubMed Web of Science ®Google Scholar
• Barnes P. J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066–1071
   PubMed Web of Science ®Google Scholar
• Yamamoto Y., Gaynor R. B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135–142
   PubMed Web of Science ®Google Scholar
• Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297–309
   PubMed Web of Science ®Google Scholar
• Aggarwal B. B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6: 203–208
   PubMed Web of Science ®Google Scholar
• Li Q., Withoff S., Verma I. M. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 2005; 26: 318–325
   PubMed Web of Science ®Google Scholar
• Karin M., Greten F. R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749–759
   PubMed Web of Science ®Google Scholar
• Luo J. L., Kamata H., Karin M. IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. J Clin Invest 2005; 115: 2625–2632
   PubMed Web of Science ®Google Scholar
• Gilmore T. D., Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 2006; 25: 6887–6899
   PubMed Web of Science ®Google Scholar
• Karin M., Yamamoto Y., Wang Q. M. The I KK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17–26
   PubMed Web of Science ®Google Scholar
• Hayden M. S., Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195–2224
   PubMed Web of Science ®Google Scholar
• Gloriam D. E., Fredriksson R., Schioth H. B. The G protein-coupled receptor subset of the rat genome. BMC Genomics 2007; 8: 338
   PubMedGoogle Scholar
• Fredriksson R., Lagerstrom M. C., Lundin L. G., Schioth H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003; 63: 1256–1272
   PubMed Web of Science ®Google Scholar
• Lagerstrom M. C., Schioth H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008; 7: 339–357
   PubMed Web of Science ®Google Scholar
• Lattin J., Zidar D. A., Schroder K., Kellie S., Hume D. A., Sweet M. J. G-protein-coupled receptor expression, function, and signaling in macrophages. J Leukoc Biol 2007; 82: 16–32
   Web of Science ®Google Scholar
• Szekanecz Z., Szucs G., Szanto S., Koch A. E. Chemokines in rheumatic diseases. Curr Drug Targets 2006; 7: 91–102
   PubMed Web of Science ®Google Scholar
• Dorsam R. T., Gutkind J. S. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7: 79–94
   PubMed Web of Science ®Google Scholar
• Spiegelberg B. D., Hamm H. E. Roles of G-protein-coupled receptor signaling in cancer biology and gene transcription. Curr Opin Genet Dev 2007; 17: 40–44
   PubMed Web of Science ®Google Scholar
• Raman D., Baugher P. J., Thu Y. M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007; 256: 137–165
   PubMed Web of Science ®Google Scholar
• Karin M., Lawrence T., Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124: 823–835
   PubMed Web of Science ®Google Scholar
• Minami M., Shimizu K., Okamoto Y., Folco E., Ilasaca M. L., Feinberg M. W., Aikawa M., Libby P. Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J Biol Chem 2008; 283: 9692–9703
   Google Scholar
• Wegener E., Krappmann D. CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB. Sci STKE 2007; 2007: pe21
   Google Scholar
• Catania A. The melanocortin system in leukocyte biology. J Leukoc Biol 2007; 81: 383–392
   Google Scholar
• Klemm S., Zimmermann S., Peschel C., Mak T. W., Ruland J. Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production. Proc Natl Acad Sci USA 2007; 104: 134–138
   PubMed Web of Science ®Google Scholar
• Han S. H., Kim J. H., Seo H. S., Martin M. H., Chung G. H., Michalek S. M., Nahm M. H. Lipoteichoic acid-induced nitric oxide production depends on the activation of platelet-activating factor receptor and Jak2. J Immunol 2006; 176: 573–579
   Google Scholar
• Loza M. J., Foster S., Peters S. P., Penn R. B. Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells. Blood 2006; 107: 2052–2060
   PubMed Web of Science ®Google Scholar
• Kumar A., Humphreys T. D., Kremer K. N., Bramati P. S., Bradfield L., Edgar C. E., Hedin K. E. CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity 2006; 25: 213–224
   PubMed Web of Science ®Google Scholar
• Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 2007; 213: 589–602
   PubMed Web of Science ®Google Scholar
• Luttrell L. M. Transmembrane signaling by G protein-coupled receptors. Methods Mol Biol 2006; 332: 3–49
   PubMedGoogle Scholar
• Mackay H. J., Twelves C. J. Targeting the protein kinase C family: are we there yet?. Nat Rev Cancer 2007; 7: 554–562
   PubMed Web of Science ®Google Scholar
• Griner E. M., Kazanietz M. G. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281–294
   PubMed Web of Science ®Google Scholar
• Skalhegg B. S., Funderud A., Henanger H. H., Hafte T. T., Larsen A. C., Kvissel A. K., Eikvar S., Orstavik S. Protein kinase A (PKA)-a potential target for therapeutic intervention of dysfunctional immune cells. Curr Drug Targets 2005; 6: 655–664
   Google Scholar
• Tasken K., Aandahl E. M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004; 84: 137–167
   PubMed Web of Science ®Google Scholar
• Holz G. G., Kang G., Harbeck M., Roe M. W., Chepurny O. G. Cell physiology of cAMP sensor Epac. J Physiol 2006; 577: 5–15
   PubMed Web of Science ®Google Scholar
• Martiny-Baron G., Fabbro D. Classical P KC isoforms in cancer. Pharmacol Res 2007; 55: 477–486
   PubMedGoogle Scholar
• Hayashi K., Altman A. Protein kinase C theta (PKCtheta): a key player in T cell life and death. Pharmacol Res 2007; 55: 537–544
   PubMed Web of Science ®Google Scholar
• Chaudhary D., Kasaian M. PKCtheta: a potential therapeutic target for T-cell-mediated diseases. Curr Opin Investig Drugs 2006; 7: 432–437
   PubMedGoogle Scholar
• El-Rayes B. F., Ali S., Philip P. A., Sarkar F. H. Protein kinase C: a target for therapy in pancreatic cancer. Pancreas 2008; 36: 346–352
   PubMed Web of Science ®Google Scholar
• Kang D. W., Park M. H., Lee Y. J., Kim H. S., Kwon T. K., Park W. S., Min S. do, Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. J Biol Chem 2008; 283: 4094–4104
   PubMedGoogle Scholar
• Park K. A., Byun H. S., Won M., Yang K. J., Shin S., Piao L., Kim J. M., Yoon W. H., Junn E., Park J., Seok J. H., Hur G. M. Sustained activation of protein kinase C downregulates nuclear factor-kappaB signaling by dissociation of IKK-gamma and Hsp90 complex in human colonic epithelial cells. Carcinogenesis 2007; 28: 71–80
   PubMed Web of Science ®Google Scholar
• Zhang P., Chan J., Dragoi A. M., Gong X., Ivanov S., Li Z. W., Chuang T. H., Tuthill C., Wan Y., Karin M., Chu W. M. Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep 2005; 6: 531–537
   PubMed Web of Science ®Google Scholar
• Garcia-Cao I., Duran A., Collado M., Carrascosa M. J., Martin-Caballero J., Flores J. M., Diaz-Meco M. T., Moscat J., Serrano M. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005; 6: 577–583
   PubMed Web of Science ®Google Scholar
• Cataisson C., Pearson A. J., Torgerson S., Nedospasov S. A., Yuspa S. H. Protein kinase C alpha-mediated chemotaxis of neutrophils requires NF-kappa B activity but is independent of TNF alpha signaling in mouse skin in vivo. J Immunol 2005; 174: 1686–1692
   Google Scholar
• Cataisson C., Pearson A. J., Tsien M. Z., Mascia F., Gao J. L., Pastore S., Yuspa S. H. CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation. J Clin Invest 2006; 116: 2757–2766
   Google Scholar
• Sun J., Ramnath R. D., Bhatia M. Neuropeptide substance P upregulates chemokine and chemokine receptor expression in primary mouse neutrophils. Am J Physiol Cell Physiol 2007; 293: C696–704
   Google Scholar
• Karagiannides I., Kokkotou E., Tansky M., Tchkonia T., Giorgadze N., O'Brien M., Leeman S. E., Kirkland J. L., Pothoulakis C. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci USA 2006; 103: 5207–5212
   Google Scholar
• Leitges M., Sanz L., Martin P., Duran A., Braun U., Garcia J. F., Camacho F., Diaz-Meco M. T., Rennert P. D., Moscat J. Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell 2001; 8: 771–780
   PubMed Web of Science ®Google Scholar
• Duran A., Diaz-Meco M. T., Moscat J. Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J 2003; 22: 3910–3918
   PubMed Web of Science ®Google Scholar
• Rawlings D. J., Sommer K., Moreno-Garcia M. E. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 2006; 6: 799–812
   PubMed Web of Science ®Google Scholar
• McAllister-Lucas L. M., Ruland J., Siu K., Jin X., Gu S., Kim D. S., Kuffa P., Kohrt D., Mak T. W., Nunez G., Lucas P. C. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci USA 2007; 104: 139–144
   PubMed Web of Science ®Google Scholar
• Grabiner B. C., Blonska M., Lin P. C., You Y., Wang D., Sun J., Darnay B. G., Dong C., Lin X. CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-κ B activation. Genes Dev 2007; 21: 984–996
   PubMedGoogle Scholar
• Wang D., You Y., Lin P. C., Xue L., Morris S. W., Zeng H., Wen R., Lin X. Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors. Proc Natl Acad Sci USA 2007; 104: 145–150
   PubMed Web of Science ®Google Scholar
• Mahanivong C., Chen H. M., Yee S. W., Pan Z. K., Dong Z., Huang S. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008; 27: 1273–1280
   PubMed Web of Science ®Google Scholar
• Klysik J., Theroux S. J., Sedivy J. M., Moffit J. S., Boekelheide K. Signaling crossroads: the function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal 2008; 20: 1–9
   PubMed Web of Science ®Google Scholar
• Kroslak T., Koch T., Kahl E., Hollt V. Human phosphatidylethanolamine-binding protein facilitates heterotrimeric G protein-dependent signaling. J Biol Chem 2001; 276: 39772–39778
   Google Scholar
• Lorenz K., Lohse M. J., Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 2003; 426: 574–579
   PubMed Web of Science ®Google Scholar
• Yeung K. C., Rose D. W., Dhillon A. S., Yaros D., Gustafsson M., Chatterjee D., McFerran B., Wyche J., Kolch W., Sedivy J. M. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 2001; 21: 7207–7217
   PubMed Web of Science ®Google Scholar
• Bijli K. M., Fazal F., Minhajuddin M., Rahman A. Activation of Syk by PKC delta regulates thrombin-induced ICAM-1 expression in endothelial cells via tyrosine phosphorylation of RelA/p65. J Biol Chem 2008; 283: 14674–14684
   PubMed Web of Science ®Google Scholar
• Sun Z., Arendt C. W., Ellmeier W., Schaeffer E. M., Sunshine M. J., Gandhi L., Annes J., Petrzilka D., Kupfer A., Schwartzberg P. L., Littman D. R. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000; 404: 402–407
   PubMed Web of Science ®Google Scholar
• Su T. T., Guo B., Kawakami Y., Sommer K., Chae K., Humphries L. A., Kato R. M., Kang S., Patrone L., Wall R., Teitell M., Leitges M., Kawakami T., Rawlings D. J. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002; 3: 780–786
   PubMed Web of Science ®Google Scholar
• Lee K. Y., D'Acquisto F., Hayden M. S., Shim J. H., Ghosh S. PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation. Science 2005; 308: 114–118
   PubMedGoogle Scholar
• Sommer K., Guo B., Pomerantz J. L., Bandaranayake A. D., Moreno-Garcia M. E., Ovechkina Y. L., Rawlings D. J. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 2005; 23: 561–574
   PubMed Web of Science ®Google Scholar
• Matsumoto R., Wang D., Blonska M., Li H., Kobayashi M., Pappu B., Chen Y., Lin X. Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation. Immunity 2005; 23: 575–585
   PubMed Web of Science ®Google Scholar
• Shinohara H., Yasuda T., Aiba Y., Sanjo H., Hamadate M., Watarai H., Sakurai H., Kurosaki T. PKC beta regulates BCR-mediated I KK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 2005; 202: 1423–1431
   PubMed Web of Science ®Google Scholar
• Shinohara H., Maeda S., Watarai H., Kurosaki T. IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J Exp Med 2007; 204: 3285–3293
   PubMedGoogle Scholar
• Pfeifhofer C., Kofler K., Gruber T., Tabrizi N. G., Lutz C., Maly K., Leitges M., Baier G. Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med 2003; 197: 1525–1535
   PubMed Web of Science ®Google Scholar
• Siebenlist U., Brown K., Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 2005; 5: 435–445
   PubMed Web of Science ®Google Scholar
• Manicassamy S., Gupta S., Sun Z. Selective function of PKC-theta in T cells. Cell Mol Immunol 2006; 3: 263–270
   PubMed Web of Science ®Google Scholar
• Healy A. M., Izmailova E., Fitzgerald M., Walker R., Hattersley M., Silva M., Siebert E., Terkelsen J., Picarella D., Pickard M. D., LeClair B., Chandra S., Jaffee B. PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis. J Immunol 2006; 177: 1886–1893
   PubMed Web of Science ®Google Scholar
• Nagahama K., Ogawa A., Shirane K., Shimomura Y., Sugimoto K., Mizoguchi A. Protein kinase C theta plays a fundamental role in different types of chronic colitis. Gastroenterology 2008; 134: 459–469
   PubMedGoogle Scholar
• Anderson K., Fitzgerald M., Dupont M., Wang T., Paz N., Dorsch M., Healy A., Xu Y., Ocain T., Schopf L., Jaffee B., Picarella D. Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases. Autoimmunity 2006; 39: 469–478
   PubMed Web of Science ®Google Scholar
• Belguise K., Sonenshein G. E. PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. J Clin Invest 2007; 117: 4009–4021
   PubMed Web of Science ®Google Scholar
• Romieu-Mourez R., Kim D. W., Shin S. M., Demicco E. G., Landesman-Bollag E., Seldin D. C., Cardiff R. D., Sonenshein G. E. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003; 23: 5738–5754
   PubMed Web of Science ®Google Scholar
• Sovak M. A., Bellas R. E., Kim D. W., Zanieski G. J., Rogers A. E., Traish A. M., Sonenshein G. E. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100: 2952–2960
   PubMed Web of Science ®Google Scholar
• Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938–6947
   PubMed Web of Science ®Google Scholar
• Cogswell P. C., Guttridge D. C., Funkhouser W. K., Baldwin A. S., Jr. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000; 19: 1123–1131
   PubMed Web of Science ®Google Scholar
• Catley M. C., Cambridge L. M., Nasuhara Y., Ito K., Chivers J. E., Beaton A., Holden N. S., Bergmann M. W., Barnes P. J., Newton R. Inhibitors of protein kinase C (PKC) prevent activated transcription: role of events downstream of NF-kappaB DNA binding. J Biol Chem 2004; 279: 18457–18466
   PubMed Web of Science ®Google Scholar
• Garg R., Ramchandani A., Maru G. Curcumin decreases 12-0-tetradecanoylphorbol-13-acetate-induced protein kinase C translocation to modulate downstream targets in mouse skin. Carcinogenesis 2008; 29: 1249–1257
   Google Scholar
• Zhou X., Yang W., Li J. Ca2+- and protein kinase C-dependent signaling pathway for nuclear factor-kappaB activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide-stimulated rat peritoneal macrophages. J Biol Chem 2006; 281: 31337–31347
   PubMed Web of Science ®Google Scholar
• Wang Q., Wang X., Zhou Y., Evers B. M. PKCdelta-mediated regulation of FLIP expression in human colon cancer cells. Int J Cancer 2006; 118: 326–334
   PubMed Web of Science ®Google Scholar
• Min J. K., Kim Y. M., Kim S. W., Kwon M. C., Kong Y. Y., Hwang I. K., Won M. H., Rho J., Kwon Y. G. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells. J Immunol 2005; 175: 531–540
   PubMed Web of Science ®Google Scholar
• Fahy B. N., Schlieman M. G., Virudachalam S., Bold R. J. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003; 113: 88–95
   PubMed Web of Science ®Google Scholar
• Sharkey J., Khong T., Spencer A. PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. Blood 2007; 109: 1712–1719
   PubMed Web of Science ®Google Scholar
• Sunahara R. K., Taussig R. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. Mol Interv 2002; 2: 168–184
   PubMedGoogle Scholar
• Bender A. T., Beavo J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488–520
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V., Spina D., Page C. P. Phosphodiesterase inhibitors. Br J Pharmacol 2006; 147(Suppl 1)S252–257
   PubMed Web of Science ®Google Scholar
• Giembycz M. A. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 326–333, discussion 340–321
   PubMedGoogle Scholar
• Giembycz M. A. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005; 5: 238–244
   PubMed Web of Science ®Google Scholar
• Conti M., Richter W., Mehats C., Livera G., Park J. Y., Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003; 278: 5493–5496
   PubMed Web of Science ®Google Scholar
• Lagente V., Martin-Chouly C., Boichot E., Martins M. A., Silva P. M. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem Inst Oswaldo Cruz 2005; 100(Suppl 1)131–136
   PubMed Web of Science ®Google Scholar
• Ghofrani H. A., Osterloh I. H., Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689–702
   PubMed Web of Science ®Google Scholar
• Schmidt M., Evellin S., Weernink P. A., Dorp von F., Rehmann H., Lomasney J. W., Jakobs K. H. A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. Nat Cell Biol 2001; 3: 1020–1024
   PubMed Web of Science ®Google Scholar
• Neumann M., Grieshammer T., Chuvpilo S., Kneitz B., Lohoff M., Schimpl A., Franza B. R., Jr., Serfling E. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J 1995; 14: 1991–2004
   PubMed Web of Science ®Google Scholar
• Parry G. C., Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol 1997; 159: 5450–5456
   PubMed Web of Science ®Google Scholar
• Zhong H., SuYang H., Erdjument-Bromage H., Tempst P., Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997; 89: 413–424
   PubMed Web of Science ®Google Scholar
• Park J. M., Greten F. R., Wong A., Westrick R. J., Arthur J. S., Otsu K., Hoffmann A., Montminy M., Karin M. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis—CREB and NF-kappaB as key regulators. Immunity 2005; 23: 319–329
   PubMed Web of Science ®Google Scholar
• Schillace R. V., Carr D. W. The role of protein kinase A and A-kinase anchoring proteins in modulating T-cell activation: progress and future directions. Crit Rev Immunol 2006; 26: 113–131
   PubMedGoogle Scholar
• Tasken K., Ruppelt A. Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts. Front Biosci 2006; 11: 2929–2939
   Google Scholar
• Bjorgo E., Tasken K. Role of cAMP phosphodiesterase 4 in regulation of T-cell function. Crit Rev Immunol 2006; 26: 443–451
   Google Scholar
• Ruppelt A., Mosenden R., Gronholm M., Aandahl E. M., Tobin D., Carlson C. R., Abrahamsen H., Herberg F. W., Carpen O., Tasken K. Inhibition of T cell activation by cyclic adenosine 5′-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol 2007; 179: 5159–5168
   PubMed Web of Science ®Google Scholar
• Kammer G. M., Laxminarayana D., Khan I. U. Mechanisms of deficient type I protein kinase A activity in lupus T lymphocytes. Int Rev Immunol 2004; 23: 225–244
   PubMed Web of Science ®Google Scholar
• Tortora G., Ciardiello F. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci 2002; 968: 139–147
   PubMedGoogle Scholar
• Cho-Chung Y. S., Nesterova M. V. Tumor reversion: protein kinase A isozyme switching. Ann N Y Acad Sci 2005; 1058: 76–86
   PubMed Web of Science ®Google Scholar
• Sanda T. Transcription factors as therapeutic targets in lymphoid malignancies. Int Rev Immunol 2007; 26: 305–332
   Web of Science ®Google Scholar
• Horie R. NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma. Int Rev Immunol 2007; 26: 269–281
   PubMed Web of Science ®Google Scholar
• Cilloni D., Martinelli G., Messa F., Baccarani M., Saglio G. Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica 2007; 92: 1224–1229
   PubMed Web of Science ®Google Scholar
• Lerner A., Kim D. H., Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma 2000; 37: 39–51
   PubMed Web of Science ®Google Scholar
• Hirsh L., Dantes A., Suh B. S., Yoshida Y., Hosokawa K., Tajima K., Kotsuji F., Merimsky O., Amsterdam A. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol 2004; 68: 981–988
   PubMed Web of Science ®Google Scholar
• Lerner A., Epstein P. M. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 2006; 393: 21–41
   PubMed Web of Science ®Google Scholar
• Chen L., Fredholm B. B., Jondal M. Adenosine, through the A1 receptor, inhibits vesicular MHC class I cross-presentation by resting DC. Mol Immunol 2008; 45: 2247–2254
   Google Scholar
• Sitkovsky M., Lukashev D., Deaglio S., Dwyer K., Robson S. C., Ohta A. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 2008; 153(Suppl 1)S457–464
   PubMedGoogle Scholar
• Gessi S., Varani K., Merighi S., Fogli E., Sacchetto V., Benini A., Leung E., Mac-Lennan S., Borea P. A. Adenosine and lymphocyte regulation. Purinergic Signal 2007; 3: 109–116
   PubMed Web of Science ®Google Scholar
• Krump E., Picard S., Mancini J., Borgeat P. Suppression of leukotriene B4 biosynthesis by endogenous adenosine in ligand-activated human neutrophils. J Exp Med 1997; 186: 1401–1406
   Web of Science ®Google Scholar
• Surette M. E., Krump E., Picard S., Borgeat P. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4). Mol Pharmacol 1999; 56: 1055–1062
   Google Scholar
• Jijon H. B., Walker J., Hoentjen F., Diaz H., Ewaschuk J., Jobin C., Madsen K. L. Adenosine is a negative regulator of NF-kappaB and MAPK signaling in human intestinal epithelial cells. Cell Immunol 2005; 237: 86–95
   PubMed Web of Science ®Google Scholar
• Fishman P., Bar-Yehuda S., Madi L., Rath-Wolfson L., Ochaion A., Cohen S., Baharav E. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 2006; 8: R33
   PubMed Web of Science ®Google Scholar
• Khoury J., Ibla J. C., Neish A. S., Colgan S. P. Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation. J Clin Invest 2007; 117: 703–711
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S., Silverman M. H., Kerns W. D., Ochaion A., Cohen S., Fishman P. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 2007; 16: 1601–1613
   PubMed Web of Science ®Google Scholar
• Brown R. A., Spina D., Page C. P. Adenosine receptors and asthma. Br J Pharmacol 2008; 153(Suppl 1)S446–456
   PubMed Web of Science ®Google Scholar
• Erdmann A. A., Gao Z. G., Jung U., Foley J., Borenstein T., Jacobson K. A., Fowler D. H. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 2005; 105: 4707–4714
   PubMed Web of Science ®Google Scholar
• Lappas C. M., Rieger J. M., Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 2005; 174: 1073–1080
   PubMed Web of Science ®Google Scholar
• Lappas C. M., Sullivan G. W., Linden J. Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 2005; 14: 797–806
   PubMed Web of Science ®Google Scholar
• Lukashev D., Ohta A., Apasov S., Chen J. F., Sitkovsky M. Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 2004; 173: 21–24
   PubMed Web of Science ®Google Scholar
• Minguet S., Huber M., Rosenkranz L., Schamel W. W., Reth M., Brummer T. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol 2005; 35: 31–41
   PubMed Web of Science ®Google Scholar
• Link A. A., Kino T., Worth J. A., McGuire J. L., Crane M. L., Chrousos G. P., Wilder R. L., Elenkov I. J. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 2000; 164: 436–442
   PubMed Web of Science ®Google Scholar
• Harada N., Okajima K., Murakami K., Usune S., Sato C., Ohshima K., Katsuragi T. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther 2000; 294: 1034–1042
   PubMed Web of Science ®Google Scholar
• Day Y. J., Li Y., Rieger J. M., Ramos S. I., Okusa M. D., Linden J. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol 2005; 174: 5040–5046
   PubMed Web of Science ®Google Scholar
• Ramanathan M., Pinhal-Enfield G., Hao I., Leibovich S. J. Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol Biol Cell 2007; 18: 14–23
   PubMed Web of Science ®Google Scholar
• Linden J. New insights into the regulation of inflammation by adenosine. J Clin Invest 2006; 116: 1835–1837
   PubMed Web of Science ®Google Scholar
• Blackburn M. R., Volmer J. B., Thrasher J. L., Zhong H., Crosby J. R., Lee J. J., Kellems R. E. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med 2000; 192: 159–170
   PubMed Web of Science ®Google Scholar
• Chunn J. L., Molina J. G., Mi T., Xia Y., Kellems R. E., Blackburn M. R. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol 2005; 175: 1937–1946
   PubMed Web of Science ®Google Scholar
• Sun C. X., Zhong H., Mohsenin A., Morschl E., Chunn J. L., Molina J. G., Belardinelli L., Zeng D., Blackburn M. R. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 2006; 116: 2173–2182
   PubMed Web of Science ®Google Scholar
• Holgate S. T. The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol 2005; 145: 1009–1015
   PubMed Web of Science ®Google Scholar
• Naderi S., Gutzkow K. B., Lahne H. U., Lefdal S., Ryves W. J., Harwood A. J., Blomhoff H. K. cAMP-induced degradation of cyclin D3 through association with GSK-3beta. J Cell Sci 2004; 117: 3769–3783
   PubMed Web of Science ®Google Scholar
• Hoang T., Fenne I. S., Cook C., Borud B., Bakke M., Lien E. A., Mellgren G. cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. J Biol Chem 2004; 279: 49120–49130
   PubMed Web of Science ®Google Scholar
• Zhang F., Hu Y., Huang P., Toleman C. A., Paterson A. J., Kudlow J. E. Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem 2007; 282: 22460–22471
   PubMedGoogle Scholar
• Jalonen U., Paukkeri E. L., Moilanen E. Compounds that increase or mimic cAMP enhance tristetraprolin degradation in LPS-treated murine J774 macrophages. J Pharmacol Exp Ther 2008; 326: 514–522
   PubMedGoogle Scholar
• Martin L., Pingle S. C., Hallam D. M., Rybak L. P., Ramkumar V. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 2006; 316: 71–78
   PubMed Web of Science ®Google Scholar
• Lee J. Y., Jhun B. S., Oh Y. T., Lee J. H., Choe W., Baik H. H., Ha J., Yoon K. S., Kim S. S., Kang I. Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett 2006; 396: 1–6
   PubMed Web of Science ®Google Scholar
• Rath-Wolfson L., Bar-Yehuda S., Madi L., Ochaion A., Cohen S., Zabutti A., Fishman P. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin Exp Rheumatol 2006; 24: 400–406
   PubMed Web of Science ®Google Scholar
• Hoskin D. W., Mader J. S., Furlong S. J., Conrad D. M., Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008; 32: 527–535
   PubMed Web of Science ®Google Scholar
• Gessi S., Merighi S., Varani K., Cattabriga E., Benini A., Mirandola P., Leung E., MacLennan S, Feo C., Baraldi S., Borea P. A. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell Physiol 2007; 211: 826–836
   PubMed Web of Science ®Google Scholar
• Jacobson K. A., Gao Z. G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006; 5: 247–264
   PubMed Web of Science ®Google Scholar
• Majumdar S., Aggarwal B. B. Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types. Oncogene 2003; 22: 1206–1218
   PubMed Web of Science ®Google Scholar
• Fishman P., Bar-Yehuda S., Madi L., Cohn I. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 2002; 13: 437–443
   PubMed Web of Science ®Google Scholar
• Madi L., Ochaion A., Rath-Wolfson L., Bar-Yehuda S., Erlanger A., Ohana G., Harish A., Merimski O., Barer F., Fishman P. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 2004; 10: 4472–4479
   PubMed Web of Science ®Google Scholar
• Fishman P., Bar-Yehuda S., Ardon E., Rath-Wolfson L., Barrer F., Ochaion A., Madi L. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res 2003; 23: 2077–2083
   PubMed Web of Science ®Google Scholar
• Ohana G., Bar-Yehuda S., Arich A., Madi L., Dreznick Z., Rath-Wolfson L., Silberman D., Slosman G., Fishman P. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 2003; 89: 1552–1558
   PubMed Web of Science ®Google Scholar
• Fishman P., Bar-Yehuda S., Ohana G., Barer F., Ochaion A., Erlanger A., Madi L. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 2004; 23: 2465–2471
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S., Madi L., Silberman D., Gery S., Shkapenuk M., Fishman P. CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 2005; 7: 85–90
   PubMed Web of Science ®Google Scholar
• Chun K. S., Surh Y. J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004; 68: 1089–1100
   PubMed Web of Science ®Google Scholar
• Telliez A., Furman C., Pommery N., Henichart J. P. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem 2006; 6: 187–208
   PubMedGoogle Scholar
• Suleyman H., Demircan B., Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007; 59: 247–258
   PubMed Web of Science ®Google Scholar
• Baraf H. S. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Curr Pharm Des 2007; 13: 2228–2236
   Google Scholar
• Frampton J. E., Keating G. M. Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs 2007; 67: 2433–2472
   PubMed Web of Science ®Google Scholar
• Howe L. R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007; 9: 210
   PubMed Web of Science ®Google Scholar
• Aparicio G. Gallego, Diaz S. Prado, Jimenez P. Fonseca, Garcia R. Campelo, Cassinello J. Espinosa, Anton L. M. Aparicio. Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer. Clin Transl Oncol 2007; 9: 694–702
   Google Scholar
• Young J. L., Jazaeri A. A., Darus C. J., Modesitt S. C. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 2008; 109: 140–145
   PubMed Web of Science ®Google Scholar
• Sugimoto Y., Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282: 11613–11617
   PubMed Web of Science ®Google Scholar
• Haynes D. R., Whitehouse M. W., Vernon-Roberts B. The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3. Immunology 1992; 76: 251–257
   PubMed Web of Science ®Google Scholar
• Paliogianni F., Kincaid R. L., Boumpas D. T. Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways. J Exp Med 1993; 178: 1813–1817
   PubMed Web of Science ®Google Scholar
• Kraan van der Pouw T. C., Boeije L. C., Smeenk R. J., Wijdenes J., Aarden L. A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995; 181: 775–779
   Google Scholar
• Takahashi H. K., Iwagaki H., Yoshino T., Mori S., Morichika T., Itoh H., Yokoyama M., Kubo S., Kondo E., Akagi T., Tanaka N., Nishibori M. Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. J Immunol 2002; 168: 4446–4454
   PubMed Web of Science ®Google Scholar
• Walker W., Rotondo D. Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 2004; 111: 298–305
   PubMed Web of Science ®Google Scholar
• Jing H., Vassiliou E., Ganea D. Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J Leukoc Biol 2003; 74: 868–879
   PubMed Web of Science ®Google Scholar
• Gray T., Nettesheim P., Loftin C., Koo J. S., Bonner J., Peddada S., Langenbach R. Interleukin-1beta-induced mucin production in human airway epithelium is mediated by cyclooxygenase-2, prostaglandin E2 receptors, and cyclic AMP-protein kinase A signaling. Mol Pharmacol 2004; 66: 337–346
   PubMed Web of Science ®Google Scholar
• Gomez P. F., Pillinger M. H., Attur M., Marjanovic N., Dave M., Park J., Bingham C. O., Al-Mussawir H., 3rd, Abramson S. B. Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J Immunol 2005; 175: 6924–6930
   PubMedGoogle Scholar
• Sheibanie A. F., Tadmori I., Jing H., Vassiliou E., Ganea D. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J 2004; 18: 1318–1320
   PubMedGoogle Scholar
• Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., Richmond A., Strieter R., Dey S. K., DuBois R. N. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006; 203: 941–951
   PubMed Web of Science ®Google Scholar
• Dendorfer U., Oettgen P., Libermann T. A. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 1994; 14: 4443–4454
   PubMed Web of Science ®Google Scholar
• Doyle S. L., O'Neill L. A. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006; 72: 1102–1113
   PubMed Web of Science ®Google Scholar
• Hull M. A., Ko S. C., Hawcroft G. Prostaglandin E P receptors: targets for treatment and prevention of colorectal cancer?. Mol Cancer Ther 2004; 3: 1031–1039
   PubMed Web of Science ®Google Scholar
• Mutoh M., Takahashi M., Wakabayashi K. Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention. Curr Pharm Des 2006; 12: 2375–2382
   PubMed Web of Science ®Google Scholar
• Rostom A., Dube C., Lewin G., Tsertsvadze A., Barrowman N., Code C., Sampson M., Moher D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann Intern Med 2007; 146: 376–389
   PubMed Web of Science ®Google Scholar
• Fraser C. C. Exploring the positive and negative consequences of NF-kappaB inhibition for the treatment of human disease. Cell Cycle 2006; 5: 1160–1163
   PubMed Web of Science ®Google Scholar
• Nagasaka T., Boulday G., Fraser C. C., Coupel S., Coulon F., Tesson L., Heslan J. M., Soulillou J. P., Charreau B. Rapid selection of differentially expressed genes in TNF[alpha]-activated endothelial cells. Mol Med 2002; 8: 559–567
   Google Scholar
• Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 671–674
   PubMed Web of Science ®Google Scholar
• Nance D. M., Sanders V. M. Autonomic innervation and regulation of the immune system (1987–2007). Brain Behav Immun 2007; 21: 736–745
   PubMed Web of Science ®Google Scholar
• Selmeczy Z., Vizi E. S., Csoka B., Pacher P., Hasko G. Role of nonsynaptic communication in regulating the immune response. Neurochem Int 2008; 52: 52–59
   Google Scholar
• Kohm A. P., Sanders V. M. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 2001; 53: 487–525
   PubMed Web of Science ®Google Scholar
• Kin N. W., Sanders V. M. It takes nerve to tell T and B cells what to do. J Leukoc Biol 2006; 79: 1093–1104
   PubMed Web of Science ®Google Scholar
• Ye R. D. beta-Adrenergic agonists regulate NF-kappaB activation through multiple mechanisms. Am J Physiol Lung Cell Mol Physiol 2000; 279: L615–617
   Google Scholar
• Farmer P., Pugin J. beta-adrenergic agonists exert their “anti-inflammatory” effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 2000; 279: L675–682
   PubMed Web of Science ®Google Scholar
• Kizaki T., Izawa T., Sakurai T., Haga S., Taniguchi N., Tajiri H., Watanabe K., Day N. K., Toba K., Ohno H. beta(2)-Adrenergic receptor regulates Toll-like receptor-4-induced nuclear factor-kappaB activation through beta-arrestin 2. Immunology 2008; 124: 348–356
   Google Scholar
• Nie M., Knox A. J., Pang L. beta2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J Immunol 2005; 175: 478–486
   PubMed Web of Science ®Google Scholar
• Pauwels R. A., Lofdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405–1411
   PubMed Web of Science ®Google Scholar
• Shrewsbury S., Pyke S., Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368–1373
   PubMed Web of Science ®Google Scholar
• Pongratz G., McAlees J. W., Conrad D. H., Erbe R. S., Haas K. M., Sanders V. M. The level of IgE produced by a B cell is regulated by norepinephrine in a p38 MAPK- and CD23-dependent manner. J Immunol 2006; 177: 2926–2938
   PubMedGoogle Scholar
• Cosentino M., Fietta A. M., Ferrari M., Rasini E., Bombelli R., Carcano E., Saporiti F., Meloni F., Marino F., Lecchini S. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 2007; 109: 632–642
   PubMed Web of Science ®Google Scholar
• Loop T., Bross T., Humar M., Hoetzel A., Schmidt R., Pahl H. L., Geiger K. K., Pannen B. H. Dobutamine inhibits phorbol-myristate-acetate-induced activation of nuclear factor-kappaB in human T lymphocytes in vitro. Anesth Analg 2004; 99: 1508–1515
   Google Scholar
• Entschladen F., Drell T. L. T., Lang K., Joseph J., Zaenker K. S. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005; 11: 403–411
   PubMed Web of Science ®Google Scholar
• Schuller H. M. Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Prog Exp Tumor Res 2007; 39: 45–63
   PubMed Web of Science ®Google Scholar
• Sastry K. S., Karpova Y., Prokopovich S., Smith A. J., Essau B., Gersappe A., Carson J. P., Weber M. J., Register T. C., Chen Y. Q., Penn R. B., Kulik G. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 2007; 282: 14094–14100
   PubMed Web of Science ®Google Scholar
• Yang E. V., Sood A. K., Chen M., Li Y., Eubank T. D., Marsh C. B., Jewell S., Flavahan N. A., Morrison C., Yeh P. E., Lemeshow S., Glaser R. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006; 66: 10357–10364
   PubMed Web of Science ®Google Scholar
• Liu X., Wu W. K., Yu L., Sung J. J., Srivastava G., Zhang S. T., Cho C. H. Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway. J Cell Biochem 2008
   Google Scholar
• Landen C. N., Lin Y. G., Jr., Armaiz G., Pena N., Das P. D., Arevalo J. M., Kamat A. A., Han L. Y., Jennings N. B., Spannuth W. A., Thaker P. H., Lutgendorf S. K., Savary C. A., Sanguino A. M., Lopez-Berestein G., Cole S. W., Sood A. K. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 2007; 67: 10389–10396
   PubMed Web of Science ®Google Scholar
• Tahmatzopoulos A., Rowland R. G., Kyprianou N. The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother 2004; 5: 1279–1285
   PubMed Web of Science ®Google Scholar
• Hui H., Fernando M. A., Heaney A. P. The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis. Eur J Cancer 2008; 44: 160–166
   PubMed Web of Science ®Google Scholar
• Liu X., Wu W. K., Yu L., Li Z. J., Sung J. J., Zhang S. T., Cho C. H. Epidermal growth factor-induced oesophageal cancer cell proliferation requires transactivation of beta-adrenoceptors. J Pharmacol Exp Ther 2008; 326: 69–75
   PubMed Web of Science ®Google Scholar